Masimo (NASDAQ:MASI) Receives Hold Rating from Jefferies Financial Group

Jefferies Financial Group reaffirmed their hold rating on shares of Masimo (NASDAQ:MASIFree Report) in a report issued on Tuesday, MarketBeat reports. Jefferies Financial Group currently has a $121.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $107.00.

A number of other equities research analysts also recently weighed in on MASI. StockNews.com downgraded shares of Masimo from a hold rating to a sell rating in a research note on Thursday, November 16th. Needham & Company LLC downgraded shares of Masimo from a buy rating to a hold rating in a research note on Wednesday, January 3rd. Raymond James downgraded shares of Masimo from an outperform rating to a market perform rating in a research note on Wednesday, November 8th. Finally, Wells Fargo & Company reduced their target price on shares of Masimo from $110.00 to $81.00 and set an equal weight rating on the stock in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of $121.86.

Read Our Latest Report on Masimo

Masimo Trading Down 1.0 %

NASDAQ:MASI opened at $128.95 on Tuesday. Masimo has a 12 month low of $75.22 and a 12 month high of $198.00. The firm has a market cap of $6.81 billion, a price-to-earnings ratio of 78.63 and a beta of 1.00. The company has a quick ratio of 1.13, a current ratio of 2.14 and a debt-to-equity ratio of 0.71. The company’s 50 day moving average is $112.54 and its 200-day moving average is $104.05.

Masimo (NASDAQ:MASIGet Free Report) last announced its earnings results on Tuesday, November 7th. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Masimo had a net margin of 4.19% and a return on equity of 14.18%. The business had revenue of $478.90 million for the quarter, compared to analyst estimates of $498.73 million. During the same quarter in the previous year, the firm posted $1.00 earnings per share. Masimo’s revenue was down 12.8% compared to the same quarter last year. Equities analysts anticipate that Masimo will post 3.49 EPS for the current year.

Institutional Trading of Masimo

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ascent Wealth Partners LLC raised its holdings in Masimo by 5.7% during the 2nd quarter. Ascent Wealth Partners LLC now owns 17,047 shares of the medical equipment provider’s stock worth $2,720,000 after purchasing an additional 921 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Masimo by 5.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 7,413 shares of the medical equipment provider’s stock valued at $1,220,000 after acquiring an additional 374 shares during the last quarter. BlackRock Inc. increased its stake in shares of Masimo by 3.0% in the 2nd quarter. BlackRock Inc. now owns 6,120,123 shares of the medical equipment provider’s stock valued at $1,007,066,000 after acquiring an additional 178,267 shares during the last quarter. Hawk Ridge Capital Management LP increased its stake in shares of Masimo by 36.6% in the 2nd quarter. Hawk Ridge Capital Management LP now owns 253,002 shares of the medical equipment provider’s stock valued at $41,631,000 after acquiring an additional 67,781 shares during the last quarter. Finally, TD Asset Management Inc increased its stake in shares of Masimo by 302.3% in the 3rd quarter. TD Asset Management Inc now owns 71,430 shares of the medical equipment provider’s stock valued at $6,263,000 after acquiring an additional 53,676 shares during the last quarter. 85.96% of the stock is owned by institutional investors.

About Masimo

(Get Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.

Further Reading

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.